On October 11, 2024, an amendment to Schedule 13G was filed with the United States Securities and Exchange Commission by Conduit Pharmaceuticals Inc., indicating a change in ownership by several related entities. The filing, known as Amendment No. 3, details the shared beneficial ownership of 2,000,000 shares of common stock by Nirland Limited, Stockton Limited, The Rowland Master Trust, and Dovet Limited, all of which are organized in Guernsey. These shares represent 2.0% of the class and are connected to a common stock warrant that became exercisable following a business combination. The entities have a joint filing agreement and may be deemed to share voting and dispositive power over the securities held by Nirland Limited. The filing clarifies that this should not be construed as an admission that the reporting persons are the beneficial owners of the reported securities for the purposes of Section 13 of the Securities Exchange Act of 1934.

On October 11, 2024, an amendment to Schedule 13G was filed with the United States Securities and Exchange Commission by Conduit Pharmaceuticals Inc., indicating a change in ownership by several related entities. The filing, known as Amendment No. 3, details the shared beneficial ownership of 2,000,000 shares of common stock by Nirland Limited, Stockton Limited, The Rowland Master Trust, and Dovet Limited, all of which are organized in Guernsey. These shares represent 2.0% of the class and are connected to a common stock warrant that became exercisable following a business combination. The entities have a joint filing agreement and may be deemed to share voting and dispositive power over the securities held by Nirland Limited. The filing clarifies that this should not be construed as an admission that the reporting persons are the beneficial owners of the reported securities for the purposes of Section 13 of the Securities Exchange Act of 1934.